133 related articles for article (PubMed ID: 38453361)
1. Promising Candidate Prognostic Biomarkers in [
Hovhannisyan-Baghdasarian N; Luporsi M; Captier N; Nioche C; Cuplov V; Woff E; Hegarat N; Livartowski A; Girard N; Buvat I; Orlhac F
J Nucl Med; 2024 Apr; 65(4):635-642. PubMed ID: 38453361
[TBL] [Abstract][Full Text] [Related]
2. Pretherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography robust radiomic features predict overall survival in non-small cell lung cancer.
Mostafa R; Abdelsamie Kandeel A; Abd Elkareem M; Nardo L; Abdelhafez YG
Nucl Med Commun; 2022 May; 43(5):540-548. PubMed ID: 35190518
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
[TBL] [Abstract][Full Text] [Related]
5. SUVmax to tumor perimeter distance: a robust radiomics prognostic biomarker in resectable non-small cell lung cancer patients.
Jiménez Londoño GA; García Vicente AM; Bosque JJ; Amo-Salas M; Pérez-Beteta J; Honguero-Martinez AF; Pérez-García VM; Soriano Castrejón ÁM
Eur Radiol; 2022 Jun; 32(6):3889-3902. PubMed ID: 35133484
[TBL] [Abstract][Full Text] [Related]
6. Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR.
Vuong D; Tanadini-Lang S; Huellner MW; Veit-Haibach P; Unkelbach J; Andratschke N; Kraft J; Guckenberger M; Bogowicz M
Med Phys; 2019 Apr; 46(4):1677-1685. PubMed ID: 30714158
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of maximum standardized uptake value on
Qiu X; Liang H; Zhong W; Zhao J; Chen M; Zhu Z; Xu Y; Wang M
Thorac Cancer; 2021 Mar; 12(6):845-853. PubMed ID: 33512768
[TBL] [Abstract][Full Text] [Related]
8. Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer?
Tankyevych O; Tixier F; Antonorsi N; Filali Razzouki A; Mondon R; Pinto-Leite T; Visvikis D; Hatt M; Cheze Le Rest C
Methods; 2021 Apr; 188():73-83. PubMed ID: 33197567
[TBL] [Abstract][Full Text] [Related]
9. Radiomics of
Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
11. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
13. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
15. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
[TBL] [Abstract][Full Text] [Related]
16. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of baseline
Dondi F; Albano D; Bellini P; Cerudelli E; Treglia G; Bertagna F
Clin Imaging; 2023 Feb; 94():71-78. PubMed ID: 36495848
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Ganem J; Thureau S; Gouel P; Dubray B; Salaun M; Texte E; Vera P
PLoS One; 2019; 14(10):e0222885. PubMed ID: 31603916
[TBL] [Abstract][Full Text] [Related]
19. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.
Ohri N; Duan F; Snyder BS; Wei B; Machtay M; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M; El Naqa I
J Nucl Med; 2016 Jun; 57(6):842-8. PubMed ID: 26912429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
